January 13, 2025 - 22:07

Inhibrx Biosciences, Inc. has entered into a significant loan agreement with Oxford Finance, aimed at bolstering its financial resources. This strategic move is expected to support the company's ongoing clinical programs, which focus on innovative therapeutic solutions. The agreement is part of Inhibrx's broader strategy to enhance its operational capabilities and accelerate the development of its product pipeline.
The financing arrangement will provide Inhibrx with the necessary capital to advance its research and development efforts, particularly in the areas of oncology and rare diseases. This funding is crucial as the company navigates the complexities of clinical trials and regulatory approvals, which are essential for bringing new therapies to market.
Inhibrx's commitment to addressing unmet medical needs through its advanced biopharmaceuticals remains steadfast. The collaboration with Oxford Finance not only reflects confidence in Inhibrx's potential but also positions the company for future growth and success in the competitive biopharmaceutical landscape.
June 15, 2026 - 10:41
Finance students’ ‘near-peer’ mentoring raises school pupils’ financial literacyA new survey from the Financial Times has found that business schools are expanding their outreach programs, with a particular focus on financial literacy for younger students. One standout...
June 14, 2026 - 23:03
Toast (TOST): Cash Flow Gains Show How Restaurant Tech Growth Is Becoming More DurableToast, Inc. is drawing attention as a high-growth stock with low debt, appealing to investors looking for expanding businesses that are also improving their bottom line. The company`s restaurant...
June 14, 2026 - 05:10
Iridium’s Aireon Buyout Reshapes Valuation Story And Financial Risk ProfileIridium Communications has announced plans to acquire the remaining stake in Aireon, the air traffic surveillance company it currently holds as a partially owned asset. The move would bring Aireon...
June 13, 2026 - 17:55
MP Materials (MP): 10 Most Promising Mid-Cap Stocks to Buy According to AnalystsMP Materials Corp. (NYSE:MP) has been named one of the 10 most promising mid-cap stocks to buy according to current analyst ratings. The rare earth mining company recently posted its financial and...